What is Follicular Lymphoma?
Follicular lymphoma, a B-cell lymphoma, is the second most common type of low-grade non-Hodgkin lymphoma (NHL). The transformation of a B-cell characterizes it into a malignant cell. Abnormal, uncontrolled growth and proliferation of malignant B-cells can lead to enlargement of specific lymph node regions; involvement of other lymphatic tissues such as the spleen or bone marrow; and spread to other bodily tissues and organs.
What are Follicular Lymphoma causes?
Follicular Lymphoma causes are not known. Unlike some cancers, they are not passed down in families. In some cases, radiation or cancer-causing chemicals, or certain infections, may be a cause. But other times there is no known cause.
What are the symptoms of Follicular Lymphoma?
Follicular Lymphoma symptoms include painless swelling of the lymph nodes in your neck, groin, stomach, or armpits, shortness of breath, fatigue, night sweats, and weight loss.
How Follicular Lymphoma affected population?
Follicular Lymphoma Epidemiology
To know more, request sample pages @Follicular Lymphoma Market Landscape
Follicular Lymphoma Market Outlook
According to DelveInsight, the Follicular Lymphoma market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the largest Follicular Lymphoma market size with USD 799 million in 2017, while Spain had the smallest market size of Follicular Lymphoma with USD 56 million in 2017.
What are the present Follicular Lymphoma market drivers?
Changing standards of care, increasing opportunities and family history aims at driving the market growth.
What are the Follicular Lymphoma market barriers?
Clinical heterogeneity, economic burden of the disease and adverse effects of the therapies are some limitations to the Follicular Lymphoma Market Growth.
Which are the leading companies in Follicular Lymphoma market?
Key Players such as Epizyme, Kite Pharma, Novartis, Roche, Regeneron, TG therapeutics, MEI Pharma, Incyte Corporation, Bayer Health, Verastem Oncology, Gilead Sciences, Xynomics Pharmaceuticals, Bristol Myeres, Takeda Oncology, and others are the leading companies in Follicular Lymphoma market.
Table of contents
1. Key Insights
2. Executive Summary of Follicular Lymphoma
3. SWOT Analysis for Follicular Lymphoma
4. Follicular Lymphoma Market Overview at a Glance
5. Disease Background and Overview
6. Epidemiology and Patient Population
7. Country Wise-Epidemiology of Follicular Lymphoma
8. Treatment
9. Guidelines
10. Unmet Needs
11. Organizations contributing toward Follicular Lymphoma
12. Patient Journey
13. Case Reports
14. Marketed Therapies
14.1. Tazverik: Epizyme
14.2. Aliqopa: Bayer Healthcare Pharmaceuticals
14.3. Copiktra: Verastem Oncology
14.4. Zydelig: Gilead Sciences
15. Combinational Therapies: Marketed
16. Emerging Therapies
16.1. Abexinostat: Xynomic Pharmaceuticals, Inc.
16.2. Umbralisib: TG Therapeutics
16.2.4. Safety and Efficacy
16.3. ME-401: MEI Pharma
16.4. Odronextamab: Regeneron Pharmaceuticals
16.5. Parsaclisib: Incyte Corporation
16.6. Kymriah: Novartis
16.7. Yescarta: Kite Pharma
16.8. Nivolumab: Bristol-Myers Squibb
16.9. Ixazomib – Takeda Oncology
17. Emerging Combinational Therapies
17.1. Ibrutinib + Rituximab
17.2. Umbralisib + Ublituximab + Bendamustine
17.3. Zanubrutinib + Obinutuzumab
18. Other Promising Therapies
19. Follicular Lymphoma: Seven Major Market Analysis
20. Market Outlook
21. Market Drivers
22. Market Barriers
23. Market Access and Reimbursement
24. Appendix
25. DelveInsight Capabilities
26. Disclaimer
27. About DelveInsight
Request sample pages for more information on Follicular Lymphoma Market Size
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/